AUTHOR SUMMARY
Understanding how normal bone mass is achieved can provide important insights into how bone diseases, such as osteoporosis, develop. During the past decade, a great deal of information has emerged showing that components of the Wnt signaling pathway within osteoblasts are crucial in establishing and maintaining normal bone mass (1) . Currently, however, it is not clear what cell type(s) express and secrete Wnt ligands to activate this signaling pathway within osteoblasts. Our work unexpectedly shows that mature osteoblasts or their progeny, such as osteocytes, are a key source of Wnt ligands and that these Wnt ligands from mature osteoblasts are crucial for bone homeostasis (Fig. P1) .
Wnt signals are required for the proper development of numerous human tissues, and alterations in Wnt signaling occur in a significant number of human diseases. Alterations in the Wnt pathway are linked to changes in bone mass in mice and humans. For example, human patients homozygous for an inactivating mutation in LRP5, which encodes a cell-surface receptor for Wnt proteins, develop osteoporosis pseudoglioma, a syndrome characterized by extremely reduced bone mass at very young ages. Conversely, individuals carrying mutations in LRP5 that decrease interaction of the protein with secreted inhibitors develop excessive bone mass. These findings and other research establish components of the Wnt signaling pathway as potential targets for the treatment of osteoporosis (2) .
Although much is known about the components of the pathway in cells that receive Wnt ligands, little is known about the cell type(s) that secrete the Wnt proteins into the bone environment to establish and maintain normal bone mass. Recent genome-wide association studies have identified the Wls/GPR177 gene as a possible candidate for mediating bone mass (3, 4) . Wls is required for any mammalian cell to secrete any Wnt protein (5). The present study set out to validate the importance of Wls function in regulating normal bone mass and to identify the cell type in which Wls functions to mediate bone growth.
We addressed this question by using genetically engineered mice in which Wls function can be deleted selectively in specific cell types. We focused on the cell type that creates the bone matrix, differentiated osteoblasts, to examine how loss of Wls from this cell type affects bone mass. Although numerous cell types within the skeletal microenvironment are capable of expressing and secreting Wnt proteins, we found that mice missing the Wls gene only in differentiated osteoblasts have extremely low bone mass. These mice usually die before they are 2 mo old and have a dramatic susceptibility to bone fracture associated with their extremely low bone mass. In vitro work using primary osteoblasts derived from these mice demonstrates cell-autonomous defects in osteoblast differentiation in cells lacking Wls. Importantly, at least some aspects of these defects can be rescued by the addition of recombinant Wnt protein to these cultures. Thus, even though numerous cell types within the skeleton are capable of expressing and secreting Wnt proteins, Wnt proteins secreted from differentiated osteoblasts are absolutely required to establish and maintain a healthy skeleton. Published studies establish that components of the Wnt signaling pathway are required within osteoblasts and osteocytes for normal bone development (1) . Our work has shown conclusively that Wnt ligands secreted from mature osteoblasts are the key source of such ligands required for normal bone development.
